TMC Secures Allseas Contract, But Regulatory Path Remains the Gating Factor

What happened

TMC announced a definitive contract with Allseas to build the world's first commercial deep-sea nodule collection system, a milestone that adds operational credibility but does not change the fundamental reliance on NOAA permitting. The DeepValue master report rates TMC a WAIT at $5.70, with the thesis focused on whether NOAA publishes a dated NEPA Notice of Intent (NOI) and scoping timeline within the next six months. Without that artifact, the stock trades on headline risk while cash burn erodes the $117.6M liquidity buffer, and the unlimited S-3ASR shelf looms as a dilution threat. The Allseas contract is a positive signal for project execution, but it does not address the two key uncertainties: the pace of the NEPA process and the terms of future financing. Until NOAA provides a concrete EIS schedule, the risk-reward remains unattractive relative to the $4.50 attractive entry identified in the report.

Implication

Investors should not chase the Allseas headlines—the regulatory timeline and dilution risk dominate. The optimal entry is near $4.50, with a catalyst only when NOAA publishes a dated NOI, or if the stock dips on a dilutive shelf takedown that still preserves upside to a permit decision.

Thesis delta

The Allseas contract shifts the narrative slightly from pure regulatory optionality to nascent operational credibility, but it does not alter the central thesis that a dated NEPA NOI is the only event that can justify a position. The thesis remains WAIT until that regulatory milestone appears; the contract alone does not de-risk the path to first commercial recovery.